Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinpro Research Solutions

Neither a doctor nor a teaching hospital

Research payments

$2,293,018

5 payments

Through program year 2025, Clinpro Research Solutions is reported as receiving $2,293,018 in research payments, across 5 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$1,751	1
2024	Research	$2,208,884	1
2023	Research	$37,273	2
2022	Research	$45,110	1

Breakdown

Who paid Research payments · program years 2022–2025

Amgen Inc. $2,210,635 2 payments
Horizon Therapeutics plc $82,383 3 payments

Studies the money was for Research payments · program years 2022–2025

P4 Uncontrolled Gout FORWARD II $2,208,884 1 payment
Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $76,633 2 payments
A Phase 4, Multicenter, Open-Label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-Administered in Patients With Uncontrolled Gout Who Have Previously Received Pegloticase Monotherapy But Did Not Maintain A Serum Uric Acid Response $5,750 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity $1,751 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.